文献速递基础与转化研究临床试验与 GCP

细胞因子介导的急性髓系白血病CAR-T治疗耐药

Cytokine-mediated CAR T therapy resistance in AML.
PubMed 文献 · Nat Med · 2024-09-27

报告12例复发或难治性急性髓系白血病成人患者接受自体抗CD123 CAR-T细胞的先导研究,CAR-T制备成功率90.4%,12例中10例发生细胞因子释放综合征(83.3%,90%CI 0.5-0.97),3例达临床缓解(25%,90%CI 0.07-0.53);髓系支持性细胞因子经激酶信号支持白血病原始细胞存活并致CAR-T耗竭,构成区别于B细胞恶性肿瘤的耐药机制。

要点

  • 自体抗CD123 CAR-T在急性髓系白血病中制备可行,但细胞因子释放综合征发生率高且临床疗效相对较差。
  • 治疗期间分泌的髓系支持性细胞因子经激酶信号支持白血病原始细胞存活,导致CAR-T耗竭。
  • CAR-T联合细胞因子信号抑制剂可能提高急性髓系白血病免疫治疗疗效并改善结局。

核心结论

  • 自体CAR-T在急性髓系白血病中制备可行,但治疗相关细胞因子释放综合征发生率高且临床疗效相对较差。
  • 治疗诱导的细胞因子促存活效应构成急性髓系白血病特有的耐药机制,区别于B细胞恶性肿瘤中所见。
  • 作者认为,CAR-T联合细胞因子信号抑制剂可能提高急性髓系白血病免疫治疗疗效并改善结局。

研究设计与样本

  • 先导研究,纳入12例复发或难治性急性髓系白血病成人患者,接受自体抗CD123 CAR-T细胞治疗(ClinicalTrials.gov标识NCT03766126)。

主要发现

  • 靶向CD123阳性细胞的CAR-T在90.4%的制备批次中成功制备。
  • 12例输注者中10例发生细胞因子释放综合征(83.3%,90%CI 0.5-0.97)。
  • 3例达到临床缓解(25%,90%CI 0.07-0.53)。
  • 细胞治疗期间分泌的髓系支持性细胞因子经激酶信号支持急性髓系白血病原始细胞存活,导致CAR-T耗竭。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the efficacy seen in B cell malignancies. Here we report a pilot study of autologous anti-CD123 CAR T cells in 12 adults with relapsed or refractory AML. CAR T cells targeting CD123+ cells were successfully manufactured in 90.4% of runs. Cytokine release syndrome was observed in 10 of 12 infused individuals (83.3%, 90% confidence interval 0.5-0.97). Three individuals achieved clinical response (25%, 90% confidence interval 0.07-0.53). We found that myeloid-supporting cytokines are secreted during cell therapy and support AML blast survival via kinase signaling, leading to CAR T cell exhaustion. The prosurvival effect of therapy-induced cytokines presents a unique resistance mechanism in AML that is distinct from any observed in B cell malignancies. Our findings suggest that autologous CART manufacturing is feasible in AML, but treatment is associated with high rates of cytokine release syndrome and relatively poor clinical efficacy. Combining CAR T cell therapies with cytokine signaling inhibitors could enhance immunotherapy efficacy in AML and achieve improved outcomes (ClinicalTrials.gov identifier: NCT03766126 ).

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Bhagwat AS, Torres L, Shestova O, et al. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024. PMID: 39333315. doi:10.1038/s41591-024-03271-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。